港股异动 | 翰森制药(03692)午前涨超4% 阿美乐获批第五项适应症 辅助治疗研究登上《柳叶刀·肿瘤学》

Core Viewpoint - Hansoh Pharmaceutical (03692) has seen a stock price increase of over 4%, currently trading at HKD 42.12, following the announcement of a new indication for its innovative drug, Amelot (Ametinib Mesylate Tablets) [1] Group 1: Regulatory Approval - On January 8, Hansoh Pharmaceutical announced that the National Medical Products Administration (NMPA) of China has issued a drug registration certificate for Amelot, approving it for use in combination with pemetrexed and platinum-based chemotherapy for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations [1] - This marks the fifth indication approved for Amelot [1] Group 2: Research Findings - Recent research results published in the prestigious oncology journal, Lancet Oncology, indicate that Amelot significantly improves disease-free survival (DFS) in patients with completely resected stage II-III B EGFR-mutant NSCLC, with good safety profiles [1]